Related Experiment Video
Updated: Jun 28, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Novel tracers and their development for the imaging of metastatic prostate cancer
Andrea B Apolo1, Neeta Pandit-Taskar, Michael J Morris
1Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Abstract:
There are presently no accurate methods of imaging prostate cancer metastases to bone. An unprecedented number of novel imaging agents, based on the biology of the disease, are now available for testing. We reviewed contemporary molecular imaging modalities that have been tested in humans with metastatic prostate cancer, with consideration of the studies' adherence to current prostate cancer clinical trial designs. Articles from the years 2002 to 2008 on PET using (18)F-FDG, (11)C-choline, (18)F-choline, (18)F-flouride, (11)C-acetate, (11)C-methionine, and (18)F-fluoro-5alpha-dihydrotestosterone in patients with metastatic prostate cancer were reviewed. Although these studies are encouraging, most focus on the rising population with prostate-specific antigen, and many involve small numbers of patients and do not adhere to consensus criteria for clinical trial designs in prostate cancer. Hence, although many promising agents are available for testing, such studies would benefit from closer collaboration between those in the fields of medical oncology and nuclear medicine.
Insights
Accurate imaging for prostate cancer bone metastases is lacking. Review of molecular imaging agents like PET scans shows promise, but studies need better clinical trial designs and collaboration.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiochemistry
Background:
- Accurate imaging of prostate cancer bone metastases remains a significant clinical challenge.
- Novel molecular imaging agents targeting prostate cancer biology are emerging.
- Current diagnostic methods lack the precision needed for effective treatment monitoring.
Purpose of the Study:
- To review contemporary molecular imaging modalities for metastatic prostate cancer.
- To assess the adherence of these studies to current clinical trial designs.
- To identify promising imaging agents and areas for improvement.
Main Methods:
- Systematic review of articles published between 2002 and 2008.
- Focus on Positron Emission Tomography (PET) using agents such as (18)F-FDG, (11)C-choline, (18)F-choline, (18)F-fluoride, (11)C-acetate, (11)C-methionine, and (18)F-fluoro-5alpha-dihydrotestosterone.
- Analysis of study populations, particularly those with rising prostate-specific antigen (PSA), and adherence to clinical trial design criteria.
Main Results:
- Several novel PET imaging agents show encouraging results for detecting prostate cancer metastases.
- Most reviewed studies focused on patients with rising PSA levels.
- A significant limitation identified was the small patient numbers and lack of adherence to consensus clinical trial design criteria.
Conclusions:
- While numerous promising molecular imaging agents are available for prostate cancer, current studies often lack rigorous clinical trial design.
- Improved collaboration between medical oncology and nuclear medicine is crucial for advancing the clinical validation of these agents.
- Standardized trial designs are needed to accurately assess the efficacy of new imaging modalities for metastatic prostate cancer.
More Related Videos
Related Concept Videos
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...